OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2022
(5)
2021
(5)
2023
(2)
2011
(2)
2025
(1)
2024
(1)
2018
(1)
2017
(1)
2014
(1)
2013
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.
Not available
S-EPMC5292791
|
biostudies-literature
Cite
Kidney Recovery and Death in Critically Ill Patients With COVID-19-Associated Acute Kidney Injury Treated With Dialysis: The STOP-COVID Cohort Study.
Not available
S-EPMC8641974
|
biostudies-literature
Cite
Global COVID-19 lockdown highlights humans as both threats and custodians of the environment.
Not available
S-EPMC8135229
|
biostudies-literature
Cite
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Not available
S-EPMC6193457
|
biostudies-literature
Cite
Results of the two incidence screenings in the National Lung Screening Trial.
Not available
S-EPMC4307922
|
biostudies-literature
Cite
The National Lung Screening Trial: overview and study design.
Not available
S-EPMC3009383
|
biostudies-literature
Cite
Reduced lung-cancer mortality with low-dose computed tomographic screening.
Not available
S-EPMC4356534
|
biostudies-literature
Cite
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Not available
S-EPMC4175521
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8830904
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets